Frequently Asked Questions
The global breast cancer liquid biopsy market was valued at USD 0.3 Billion in 2022.
The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% between 2023 and 2030, reaching USD 1.25 Billion in 2030.
Circulating tumor cells (CTCs) are the leading segment by circulating biomarkers, holding over 35% share in terms of value in 2022.
The hospitals & physician laboratories segment governs the global demand for breast cancer liquid biopsy, holding a massive share of over 35% in 2022.
The cell-free DNA (cfDNA) segment will post the highest CAGR in the projected period.
Asia Pacific is fueling the rapid growth of the breast cancer liquid biopsy industry, with an over one-third share in 2022.
The top players include The Menarini Group, F. Hoffmann-La Roche Ltd, QIAGEN, and Thermo Fisher Scientific Inc. Other major players include NeoGenomics Laboratories, Myriad Genetics Inc, Biocept Inc, and Fluxion Biosciences Inc.
The rising prevalence of breast cancer, the increased need for non-invasive diagnostic procedures, and developments in liquid biopsy technology are the key market drivers.
The major market restraints are the high costs associated with liquid biopsy tests, regulatory challenges, and the need for skilled healthcare professionals trained in liquid biopsy techniques.
The major market opportunities of the breast cancer liquid biopsy industry include the potential for early detection of tumor recurrence, the ability to monitor treatment response, and the development of innovative liquid biopsy technologies that enhance sensitivity and accuracy.